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Background: Decision aids offer promise as a practical solution to improve patient decision making about coronary
heart disease (CHD) prevention medications and help patients choose medications to which they are likely to
adhere. However, little data is available on decision aids designed to promote adherence.
Methods: In this paper, we report on secondary analyses of a randomized trial of a CHD adherence intervention
(second generation decision aid plus tailored messages) versus usual care in an effort to understand how the
decision aid facilitates adherence. We focus on data collected from the primary study visit, when intervention
participants presented 45 minutes early to a previously scheduled provider visit; viewed the decision aid, indicating
their intent for CHD risk reduction after each decision aid component (individualized risk assessment and education,
values clarification, and coaching); and filled out a post-decision aid survey assessing their knowledge, perceived
risk, decisional conflict, and intent for CHD risk reduction. Control participants did not present early and received
usual care from their provider. Following the provider visit, participants in both groups completed post-visit surveys
assessing the number and quality of CHD discussions with their provider, their intent for CHD risk reduction, and
their feelings about the decision aid.
Results: We enrolled 160 patients into our study (81 intervention, 79 control). Within the decision aid group, the
decision aid significantly increased knowledge of effective CHD prevention strategies (+21 percentage points;
adjusted p<.0001) and the accuracy of perceived CHD risk (+33 percentage points; adjusted p<.0001), and
significantly decreased decisional conflict (-0.63; adjusted p<.0001). Comparing between study groups, the decision
aid also significantly increased CHD prevention discussions with providers (+31 percentage points; adjusted
p<.0001) and improved perceptions of some features of patient-provider interactions. Further, it increased participants’
intentions for any effective CHD risk reducing strategies (+21 percentage points; 95% CI 5 to 37 percentage points),
with a majority of the effect from the educational component of the decision aid. Ninety-nine percent of participants
found the decision aid easy to understand and 93% felt it easy to use.
Conclusions: Decision aids can play an important role in improving decisions about CHD prevention and increasing
patient-provider discussions and intent to reduce CHD risk.
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Promoting use and effective adherence to coronary heart
disease (CHD) prevention medications is integral to im-
proving preventive care and reducing healthcare costs
[1-4]. However, it raises challenges for both patients and
providers. Challenges fall broadly in two categories:
those related to improving decision making and patients’
intent to initiate one or more similarly effective medica-
tions for CHD risk reduction, and those related to support-
ing adherence.
Challenges related to improving decision making
include overcoming patients’ lack of knowledge about
CHD risk factors [2,3], their CHD risk [4], and the
potential benefits of risk reducing strategies [5-8]. They
also include helping patients clarify their values for
various heart disease prevention strategies [9,10] and
communicate effectively with their provider to align
their treatment priorities [11-24].
Challenges related to supporting adherence include
fostering patients’ confidence and skills for adherence
and marshaling adequate health system and social
support to ensure the likelihood of patients’ success [14].
Most work to date has focused on these latter issues
related to adherence with relatively little work focusing
on improving patients’ decision making about initiation
of medications [25,26].
To improve decision making, some have recom-
mended use of decision aids. Decision aids are multi-
media tools designed to convey health information, help
patients clarify their values, choose health options that
are consistent with their values and resources, and com-
municate their treatment priorities to their provider.
[27] Systematic reviews have shown that decision aids
improve patient knowledge and values clarity, and in-
crease the likelihood of making decisions [27]. However,
few decision aids have been studied in the adherence
context [26,28-31]. Further, none to our knowledge has
focused on the choice among several similarly effective
medications to reduce CHD risk, helped patients to clar-
ify their values and communicate their treatment prefer-
ences to their provider, or coupled decision-making with
tailored messages to overcome barriers to adherence.
In this paper, we report on the secondary outcomes of
a randomized trial of a CHD adherence intervention.
We have already reported that the overall intervention
(second generation decision aid plus tailored adherence
messages to overcome barriers to adherence) is effective
in improving self-reported adherence (+25 percentage
points, 95% CI 8 to 42%) and reducing 10-year predicted
CHD risk (-1.1 absolute percentage points, 95% CI -0.16%
to -2%) at 3-month follow-up [32]. Now, in an effort to
further understand how our intervention produced these
effects, we examine the independent effects of the decision
aid on patients’ knowledge, accuracy of risk perception,decisional conflict, values clarity, patient-provider interac-
tions, and intentions for CHD risk reduction. We also
examine intent for CHD risk reduction across the various
components of the decision aid (education, values clarifica-
tion, and coaching to discuss CHD risk reduction with the
provider) and report on patients’ use and overall percep-
tions of the decision aid.
Methods
Overview
We conducted a randomized trial of a CHD adherence
intervention called Heart to Heart at one university gen-
eral internal medicine practice. Detailed methods of this
trial and its main outcomes are described elsewhere
[32]. A brief overview of the trial and details about the
decision aid and measurement of decision making out-
comes are provided below. Prior to study participation,
participants provided written informed consent for study
participation. The University of North Carolina at Chapel
Hill’s Biomedical Institutional Review Board (IRB) ap-
proved all study procedures.
Setting
We conducted our study in one university internal
medicine clinic, which employs 93 providers (17 attend-
ings and 76 residents) who were not part of our research
team and eligible to participate in the study, allowing us
to enroll their patients. Forty of these providers agreed
to participate in the study and allow us to enroll their
patients and 24 had patients who agreed to enroll in the
study.
Participants
Patients were eligible for participation in the study if
they were presenting for care with an enrolled provider,
were between 40-79 years old, had no prior history of
cardiovascular disease, diabetes mellitus, or other serious
medical condition that limited their life expectancy to
less than five years, and were at moderate (6-10%) to
high (>10%) risk of heart disease over the next 10 years
based on a Framingham risk equation [33]. Detailed
exclusion criteria are published elsewhere [32].
Study procedure
After collecting baseline measures at an initial study
visit, we centrally randomized patients to either the
intervention or control (usual care) group and saw them
for two additional study visits over 3 months. This paper
focuses on data collected at the second or “primary”
study visit.
At this visit, patients randomized to the intervention
group presented 45 minutes early to a previously sched-
uled provider visit, viewed the decision aid, answered
questions about intent for CHD risk reduction embedded
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decision aid survey assessing their knowledge, accuracy of
risk perception, decisional conflict, values clarity, and
intent for CHD risk reduction. Patients randomized to the
control group did not present early to their previously
scheduled clinic visit and received usual care from their
provider. Following the provider visit, a research assistant
gave self-administered post-visit surveys to participants in
both groups to complete. Post-visit surveys assessed partic-
ipants’ discussions with their providers, and their intent for
CHD risk reduction.
Intervention
Our intervention consisted of two parts: a decision aid
delivered prior to a provider visit (at the primary study
visit) and a series of three tailored adherence messages
delivered between the primary and follow-up study
visits. In this paper, we focus on the independent effects
of the decision aid, which includes three components:
individualized risk assessment and education; values
clarification; and coaching [32]. In contrast to our earlier
CHD prevention decision aid [34], this second gener-
ation decision aid was professionally developed by the
Communications for Health Applications and Interven-
tions Core at the University of North Carolina at Chapel
Hill (www.chaicore.com) and incorporates graphics and
photographs to increase engagement with the informa-
tion provided. It also includes values clarification and
coaching in addition to education.
The individualized risk assessment and education
component of our decision aid calculates a patient’s glo-
bal risk of CHD events (e.g. angina, myocardial infarc-
tion, and death) in the next 10 years using a continuous
Framingham equation [33] and then provides patients
with individualized information about their global CHD
risk, their personal risk factors, the pros and cons of pertin-
ent CHD risk-reducing therapies (which may include
aspirin, hypertension medications, cholesterol medications,
and smoking cessation), and the risk reduction achievable
after one or more risk-reducing therapies. It concludes by
asking participants which risk reducing option they plan to
pursue, reinforcing commitment to action.
The values clarification component helps individuals
further clarify which risk reducing strategy they might
pursue (i.e. which is most concordant with their values
and would best allow them to adhere over time) by
employing an explicit ranking and rating values clarifica-
tion exercise. The ranking and rating exercise asks indi-
viduals to rank and rate attributes (e.g. benefit for other
medical conditions, side effects, degree of difficulty in
adherence for most people, cost, and effect on others)
common to each of the treatment options in the decision
aid [35]. It then summarizes their responses and asks them
which risk reducing option they plan to pursue.The coaching tool 1) outlines the benefits of partici-
pating with the provider in decision making about CHD
risk reduction (e.g. learning about special issues unique
to one’s health, getting information about resources that
may help them accomplish their plan), 2) provides a
menu of seven common barriers people have in talking
with their provider about their plans (e.g. the provider
decides the agenda, the provider uses too much medical
talk, the provider does not acknowledge previous suc-
cesses), and 3) provides audio clips matched with still
photos of a narrator and patients talking about simple
practical ways to overcome common barriers. Partici-
pants could explore any number of these barrier mes-
sages (none to seven) according to their interest and
need. To increase relevance and engagement for individ-
uals, the coaching tool includes photographs and voices
representing diverse age and race/ethnicity groups.
At the end of the decision aid, all participants receive
a summary of their Heart to Heart session that they can
take to their provider to initiate discussion [32].
Measures
Effect of the decision aid on knowledge and accuracy of
risk perception
To assess participants’ knowledge of effective CHD pre-
vention strategies, we conducted within-group compari-
sons of intervention participants’ knowledge at baseline
and immediately post-decision aid. We asked, “What
things do you think a person can do to lower his/her
chances of heart disease?”, followed by a list that in-
cluded strategies such as taking aspirin, blood pressure,
and cholesterol medicine; stopping smoking; changing
diet; and increasing physical activity. For each individual
strategy, we measured the proportion of participants indi-
cating “yes.” We then combined “yes” answers to aspirin,
blood pressure and cholesterol medicine, and smoking ces-
sation to create a composite reflecting knowledge of the
“most effective strategy”.
We also conducted a within-group comparison of
intervention participants’ accuracy of risk perception at
baseline and post-decision aid. To measure accuracy of
risk perception, we asked participants, “What do you
think is your chance of developing heart disease in the
next 10 years?” Answers included “less than 5%”; “6 to
10%”; “11 to 20%”; and “greater than 20%.” When partic-
ipants’ calculated global CHD risk fell into the category
they indicated on the survey, we categorized them as
having an accurate risk perception.
Effect of the decision aid on decisional conflict and
values clarity
To assess decisional conflict and values clarity, we con-
ducted within-group comparisons of the intervention
group at baseline and post-decision aid. To assess
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examining several features of conflicted decision making,
including feeling uncertain, uninformed, unclear about
one’s values, unsupported, or ineffective in making choices
[36]. We summed and averaged responses for this scale,
with scores ranging from 1 to 5. Scores less than 2 indicate
low conflict and are associated with intent to make and
implement a decision immediately.
To assess values clarity, we measured agreement with
the statement, “My decision shows what is important to
me.” Participants provided answers on a 5-point Likert
scale dichotomized to strongly agree/agree versus all
others.
Effect of the decision aid on patient-provider discussions and
patients’ perceptions of their interaction with their provider
To determine the effect of the decision aid on patient-
provider discussions, we assessed visit content in the
intervention and control groups immediately using ques-
tions adapted from a prior study of prostate cancer
screening [37].
We measured CHD discussions with the question,
“Did you and your provider talk about lowering your
chances of heart disease today?” If participants did re-
port having a discussion, they reported who brought up
the discussion (patient or provider), how much they par-
ticipated in the discussion (a lot, some, a little, none),
and who made the final clinical decision about CHD
prevention (provider alone, provider and patient, patient).
In this paper, we dichotomized participation in the discus-
sion into any versus none and final decisions into shared
(provider and patient) versus other.
To capture the effects of the coaching component of
the decision aid, we measured patients’ perceptions of
their interaction with their provider (e.g. “I feel my pro-
vider provided me with choices and options about lowering
my chances of heart disease”; “My provider tried to under-
stand how I see things before suggesting new ways to lower
my chances of heart disease”) using the short-form 6-item
Healthcare Climate Questionnaire. This scale is modified
from the full 15-item measure [38] and has an alpha reli-
ability of 0.82 (http://www.selfdeterminationtheory.org/
questionnaires/10-questionnaires/81). Answers were mea-
sured on a 5-point Likert scale dichotomized to strongly
agree/agree versus all others.
Participant intentions for CHD risk reduction across the
decision aid
To assess the effectiveness of our decision aid overall
and its components individually, we measured partici-
pants’ intentions to lower CHD risk among those eligible
for intervention at various times across our study: at
baseline and post-clinic visit in both the intervention
and control groups, and additionally at multiple timesduring decision aid viewing in the intervention group
(e.g. after the educational component, after the values
clarification component, and after the completion of the
entire decision aid). We assessed intention to lower CHD
risk by asking, “Are you planning to lower your chances
of heart disease?” We recorded participants’ intentions
for risk reduction strategies singly and in combination by
creating a composite “any effective CHD risk reducing
strategy” variable that recorded intent to start any one of
the effective risk reducing interventions that were a focus
of our intervention (take aspirin, blood pressure, or chol-
esterol medication and/or to stop smoking).
Participants’ use of and feelings about the decision aid
To assess tool use, we electronically tracked total time
spent with the decision aid; content of information re-
ceived (including which informational links participants
accessed); number of times participants recalculated
their CHD risk; and which links participants followed
about communicating with their provider. We did not
solicit participants’ satisfaction with the time they spent
with the tool, nor did we solicit free text comments
about the decision aid. To summarize participants’ use
of the decision aid, we calculated the mean and range of
time spent with the tool and then stratified the mean
amount of time spent with the tool by CHD risk level
(0-5%, 6-10%, 11-20%, or >20%) and number of risk re-
ducing options. We also calculated the mean number of
times participants recalculated their CHD risk and again
stratified by the number of CHD risk reducing options.
Finally, we calculated frequencies for the number of par-
ticipants accessing various informational links in the tool
(including links for risk reducing options and for bar-
riers to communicating with one’s provider) and for the
number of participants ranking decisional attributes as
“most important.”
To assess participants’ feelings about the decision aid,
we calculated the frequencies of individuals who re-
ported they agreed or strongly agreed with process state-
ments such as “Heart to Heart helped me decide what’s
important to me” and “Heart to Heart helped me make
a decision that I could stick with”.
Analyses
All analyses were conducted using SAS 9.2 Statistical
Software (Cary, NC). To assess the success of ran-
domization, we compared the baseline characteristics of
subjects who received the intervention and those who
did not. We adjusted all subsequent between-group ana-
lyses for identified appreciable differences.
To assess the effects of our decision aid on measures of
decision making (including knowledge, accuracy of risk
perception, decisional conflict, and values clarity), we con-
ducted within-group comparisons. We used McNemar’s
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t-tests for continuous variables and calculated the
absolute difference from baseline to post-decision aid. All
analyses accounted for the random effects of clustering of
patients within providers.
To assess the effects of the decision aid on patient-
provider discussions and patients’ perceptions of the
visit, we used between group comparisons. We com-
pared control and intervention groups’ responses using
Rao-Scott chi-square tests. We additionally used mixed
effects logistic regression models to calculate the abso-
lute difference between groups, adjusting for both the
baseline difference in education as a fixed effect and
clustering within providers as random effect.
To assess the effect of the intervention on intent for
adopting CHD risk reduction strategies, we again made
between group comparisons post-clinic visit using Rao-
Scott chi-square tests and, subsequently, mixed effects
logistic regression models to adjust for the baseline dif-
ferences in education and the natural effect of clustering
of patients within providers.
To report on participants’ use of and feelings about
the decision aid, we used descriptive analysis. We add-
itionally used Spearman correlation coefficients to exam-
ine the relationship between time spent with the tool
and education, comfort using a computer, CHD risk
level, and the number of options for risk reduction.
Sample size
Power was not calculated specifically for the secondary
outcomes presented in this paper.
Results
Participant demographics
Our sample includes 24 eligible providers who had
patients enrolled in the study and 160 eligible patients.
In general, patients were mostly white, male, had at
least some college education and at least a good self-
perceived health status. Mean age was 63. Most patients
expressed a preference for shared decision making about
CHD prevention (see Table 1). Groups were similar
except that a higher proportion of individuals in the
intervention group (98%) compared to the control group
(82%) reported having at least some college education.
Effect of decision aid on knowledge and accuracy of risk
perception
After viewing the decision aid, participants in the inter-
vention group had greater knowledge of effective CHD
prevention strategies (see Table 2 for analyses adjusted
for the effect of clustering of patients within providers).
Knowledge of hypertension medication (+9 percentage
points; adjusted p = .09), cholesterol medication (+17 per-
centage points; adjusted p < .01), and daily aspirin use(+27 percentage points; adjusted p < .0001) increased
across the intervention, as did knowledge of all four effect-
ive CHD prevention strategies (hypertension and choles-
terol medication, smoking cessation, and aspirin use; +28
percentage points, adjusted p < .0001). Moreover, the pro-
portion of participants who accurately perceived their
CHD risk also significantly increased (+33 percentage
points; adjusted p < .0001).
Effect of decision aid on decisional conflict and values
clarity
After viewing the decision aid, participants had signifi-
cantly lower decisional conflict (baseline = 2.57; post-
decision aid = 1.94; absolute difference -0,63; adjusted
p < .0001) and crossed the threshold (e.g. decisional
conflict between 2.5 and 2) believed to distinguish inaction
from action. After viewing the decision aid, participants
also tended to increase their self-reported values clarity
(+15 percentage points, adjusted p = .02).
Effect of decision aid on patient-provider discussions,
and patients’ perceptions of their interaction with their
provider
Participants in the intervention group were signifi-
cantly more likely to have CHD prevention discussions
with their provider than participants in the control
group after adjustment for baseline differences in edu-
cation and clustering of patients within providers (+31
percentaqe points; 95% CI 15 to 45 percentage points;
adjusted p < .001). (See Table 3) Intervention partici-
pants were also more activated, with a tendency to
more frequently raise the topic of CHD prevention
(+28 percentage points; adjusted p = .02) and to par-
ticipate more in the discussion (+28 percentage points;
adjusted p = .01).
Intervention participants also tended to report better
interactions with their provider, with improvements for
the following 3 of 6 items from the Healthcare Climate
Questionnaire: “My provider provided me with choices
and options about lowering my chances of heart disease”
(+15 percentage points; adjusted p = .02); “My provider
listened to how I would like to do things” (+21 percent-
age points; adjusted p < .01); and “My provider tried to
understand how I see things before suggesting new ways
to lower my chances of heart disease” (+15 percentage
points; adjusted p = .05). There were no significant
differences in the proportion of patients reporting: “My
provider understands how I see things with respect to
lowering my chances of heart disease” (+9 percentage
points; adjusted p = .21); “My provider conveyed confi-
dence in my ability to make changes regarding lowering
my chances of heart disease” (+11 percentage points;
adjusted p = .15); and “My provider encouraged me to
ask questions” (+11 percentage points; adjusted p = .13).
Table 1 Baseline participant characteristics
Characteristic Total group N = 160* Control group N = 79 Intervention group N = 81
Mean age 63 64 63
Female 28% 28% 27%
Race:
White 86% 84% 88%
Black 10% 10% 10%
Education:
At least some college 90% 82% 98%
CHD risk factors
BP > 140/90 36% 37% 35%
TC/HDL ratio > 4 52% 51% 53%
Smoker 13% 13% 14%
Family history of CHD (age < 55) 23% 25% 21%
Mean CHD risk 11.3 11.4 11.2
Current risk reducing strategies:
Blood pressure med 56% 61% 51%
Cholesterol med 29% 27% 31%
Smoking cessation 3% 4% 2%
Aspirin 44% 47% 42%
Diet low in saturated fat 58% 58% 58%
Exercise regularly 58% 54% 62%
Self-efficacy to lower at least 1 CHD risk factor 98% 96% 99%
Comfort using computer 91% 90% 93%
Any planned effective risk reducing strategy† 27% 25% 28%
Preferred participation in decision making about CHD:
Share decision 86% 90% 82%
Do not share decision 14% 11% 19%
Accurately identified most effective strategies for risk reduction 53% 51% 54%
Accurately perceives CHD risk 24% 14% 34%
Decisional conflict 2.53 2.49 2.57
Decision consistent with values 69% 69% 68%
*160 participants at baseline; 3 missed Primary Study Visits and 3 missed follow-ups.
†This includes hypertension medicine, cholesterol medicine, smoking cessation, aspirin.
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risk reduction
Following their visit with their provider, participants in
the intervention group were more likely to plan any of
the effective CHD risk reducing strategies that were a
focus of our intervention (e.g. aspirin, blood pressure
medicine, cholesterol medicine, smoking cessation) than
participants in the control group (+21 percentage points;
95% CI 5-37 percentage points) (see Table 4). Differences
in intentions were greatest for intent to take aspirin (+19
percentage points; 95% CI -1 to 39 percentage points)
and cholesterol medication (+30 percentage points; 95%
CI 14 to 46 percentage points).Changes in intentions to start any effective CHD risk
reducing strategy were most pronounced after the edu-
cation component of the decision aid (+34 percentage
points), and changed little with additional viewing on
the values clarification and coaching components of the
decision aid. These patterns were fairly consistent for
intent to start individual CHD prevention therapies.
However, there was a trend for reduced intent to take
hypertension medication following the provider visit.
Participants’ use of the decision aid
Participants spent an average of 12 minutes with the
Heart to Heart decision aid (standard deviation 7 minutes;
Table 2 Effect of the Decision Aid on Knowledge, Accuracy of Risk Perception, and Values Clarity
Intervention group Absolute difference Adjusted p-value*
Baseline Post-DA
Effect on knowledge
Identified “x” as strategy:
Hypertension med 78% 87% +9% =.09
Cholesterol med 73% 90% +17% <.01
Smoking cessation 100% 96% -4% –
Aspirin daily 68% 95% +27% <.0001
Diet low in saturated fat 94% 96% +2% =.32
Exercise regularly 100% 99% -1% –
Accurately identified most effective strategies for risk reduction 54% 82% +28% <.0001
Effect on accuracy of risk perception
Accurately perceives risk 34% 67% +33% <.0001
Effect on decision
Decisional conflict† 2.57 1.94 -0.63 <.0001
Decision consistent with values‡ 68% 83% +15% =.02
*Adjusted for clustering within providers.
†On alternate 0-100 scale: Baseline = 39.3; Post decision-aid = 23.5; absolute difference = -15.9; p < .0001.
‡From question: “My decision shows what is important to me”.
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5 minutes, 30% spent 6-10 minutes, 34% spent 11-15 mi-
nutes, 18% spent 16-20 minutes, and 11% spent 21 or more
minutes. Time spent with the tool did not differ by CHD
risk level (10-year predicted CHD risk <0-5%, 6-10%,Table 3 Effect of decision aid on patient-provider discussions
C
Had CHD discussion with their provider
Patient raised discussion
Patient participation
Any
None
Who made final decision
Shared decision
Not shared decision
Patients’ perceptions of discussions and the health care visit
My provider provided me with choices and options about lowering my
chances of heart disease.
My provider understands how I see things with respect to lowering my
chances of heart disease.
My provider conveyed confidence in my ability to make changes
regarding lowering my chances of heart disease.
My provider encouraged me to ask questions.
My provider listened to how I would like to do things.
My provider tried to understand how I see things before suggesting new
ways to lower my chances of heart disease.
*Adjusted for clustering within providers.
†Adjusted for baseline education and clustering within providers.11-20%, or >20%). It did, however, vary by education
(Spearman rho -0.29) and comfort using the computer
(Spearman rho 0.34). Participants recalculated their CHD
risk an average of two times (range 1-6), and appropri-
ately recalculated their risk more times as their numberontrol group
(n = 78)
Intervention group
(n = 79)
Absolute difference
(95% CI)*
Adjusted
p-value†
58% 89% 31% (15% to 45%) p < 0.001
35% 63% +28% (9% to 45%) p = .02
51% 79% +28% (9% to 45%) p = .01
49% 21% -28% (-45% to -9%)
93% 84% -9% (-27% to 10%) p = .09
7% 16% +9% (-10% to 27%)
76% 91% +15% (-0.1% to 31%) p = .02
86% 95% +9% (-7% to 25%) p = .21
77% 88% +11% (-5% to 27%) p = .15
67% 78% +11% (-4% to 27%) p = .13
71% 92% +21% (6% to 37%) p < .01
69% 84% +15% (-0.3% to 31%) p = .05
Table 4 Effect of decision aid and patient-provider discussions on patient intent for CHD risk reduction among those eligible for risk reduction
Planned CHD interventions Control group Intervention group Adj. absolute difference
between control and
intervention, post visit
(95% CI)*
Baseline
(95% CI)
Post-visit
(95% CI)
Baseline
(95% CI)
Post-education
(95% CI)
Post-values clarification
(95% CI)
Post-coaching
(95% CI)
Post-visit
(95% CI)
Any effective CHD risk reducing
Strategy† (n = 157)
25% 42% 28% 62% 61% 57% 63% 21%
(15-36%) (32-52%) (21-36%) (50-75%) (49-73%) (45-69%) (49-77%) (5% to 37%)
BP med, if HTN (n = 55 ) 3% 29% 11% 65% 65% 37% 26% -3%
(0-11%) (5-52%) (0-24%) (40-91%) (45-86%) (45-81%) (7-45%) (-30% to 25%)
Cholesterol med, if abnormal chol (n = 69) 12% 9% 5% 59% 59% 47% 39% 30%
(0-26%) (1-18%) (0-13%) (43-75%) (44%-74%) (28-67%) (24-54%) (14% to 46%)
Smoking cessation, if smoking (n = 21) 60% 50% 82% 70% 80% 80% 80% 30%
(25-95%) (8-92%) (56-100%) (35-100%) (50-100%) (50-100%) (51-100%) (-16% to 76%)
Aspirin, if CHD risk >6% and no
contra-indication (n = 140)
12% 24% 14% 40% 40% 47% 43% 19%
(8-17%) (14-33%) (6-21%) (27-54%) (29-52%) (31-63%) (24-62%) (-1% to39%)
Diet low in saturated fat, all (n = 157) 23% 40% 20% 46% 29% -11%
(12-34%) (29-51%) (12-28%) – – (44-65%) (16-42%) (-27% to 6%)
Exercise regularly, all (n = 157) 35% 54% 34% – – 56% 53% -1
(24-47%) (39-69%) (23-45 %) (42-69%) (44-62%) (-17 to 16)
*Adjusted for random effects of clustering within provider.
†Includes strategies that were the focus of our intervention: aspirin, blood pressure medicine, cholesterol medicine, smoking cessation.
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with 2 options recalculated an average of 2.6 times and
those with 4 options recalculated an average of 3.5
times). Over 20% of participants accessed links providing
additional information about the effects of aspirin, chol-
esterol medicine, diet, and exercise. Only 13% and 3%
accessed informational links about blood pressure medi-
cine and smoking, respectively.
Participants indicated different values that were im-
portant to them with respect to CHD prevention, with
“level of difficulty” as the most important (51%), fol-
lowed by “other health benefits” (31%) and “side effects”
(12%). Participants most commonly accessed the follow-
ing links for barriers to communicating with their pro-
vider: “I respect my provider, so I agree to his/her plans
even though I know I won’t stick to them” (27%); “My
provider recommends medicine, but I want to change
my lifestyle” (21%); and “I want different treatment op-
tions than my provider recommends” (14%). Other links
were accessed less frequently.
Participants’ feelings about the decision aid
Most participants found the decision aid easy to use
(92%); easy to understand (99%); and said it personalized
information for them (90%). Almost 80% of participants
reported the decision aid helped them decide what was
important to them and helped them make a decision to
which they could adhere. Seventy-one percent reported
the printout they received after viewing the decision
aid would help them to start a conversation with their
provider.
Discussion
We developed a CHD prevention intervention that in-
cluded a decision aid that participants found easy to use
and understand and said helped them to make decisions
about medications to which they could adhere. The deci-
sion aid increased participants’ readiness to make CHD
prevention decisions by increasing knowledge, accuracy
of risk perception, and values clarity, and by decreasing
decisional conflict. The decision aid further increased
the proportion of CHD prevention discussions with pro-
viders, patients’ perceptions that at least some features
of patient-provider interactions were more favorable,
and patients’ intentions for any effective risk reducing
strategy. The majority of the impact of the decision aid
on patients’ intent to start CHD prevention interven-
tions appeared to result from the educational compo-
nent of our decision aid.
Our findings are consistent with prior systematic re-
views, which suggest that decision aids improve patient
knowledge, increase the likelihood of making decisions,
and improve patient-provider discussion [27,39]. Our
research, however, suggests that much of the impact ofdecision aids on intent to start any medical therapy for
CHD prevention may result largely from education
about CHD risk (with implicit values clarification) alone.
We were unable to detect any changes in intent for spe-
cific therapies with explicit clarification of values through
our ranking and rating values clarification process. Fur-
ther, coaching to improve the patient-provider inter-
action and provider visits did not appear to affect intent
(except for a trend toward reduced hypertension medica-
tion following the provider visit). However, this needs
replication in large comparative effectiveness trials or
studies of other design that randomize the order of deci-
sion aid components.
Moving forward, researchers should consider how to
make interventions more effective in promoting use and
adherence to effective treatment strategies. For instance,
researchers might include information about drug for-
mulary coverage into decision aids so that patients can
make even more informed choices about the best pos-
sible risk reducing strategies: those consistent with per-
sonal preferences and values and with few barriers to
adherence. They might also incorporate messages that
address possible misconceptions for those who make no
plans to pursue any of the available and effective treat-
ment options. In our study, we delivered such mes-
sages as tailored messages after the clinical visit (see
Additional file 1). However, incorporation of such mes-
sages into the decision aid might improve clinical effi-
ciency by allowing completion of decision making at the
point of care. Finally, researchers might consider strat-
egies for maximizing information delivery. Users in our
study infrequently (~20%) accessed links for additional
information (e.g. exact bleeding rates with aspirin) which
may have influenced decision making. Similarly, relatively
few participants accessed each coaching message (<30%
for any given message), raising the question of whether
decision aids should be designed to force individuals to
proceed through all parts of a decision aid, or whether
patients should be able to choose the information they
want to view.
Future research should also give attention to the best
ways to implement decision aids such as ours into clin-
ical and public health practice. CHD prevention decision
aids are not only responsive to recent national cam-
paigns (e.g. The Million Hearts Campaign) that call for
the use of internet technology to help identify and sup-
port patients at elevated risk of CHD [40], but they also
have the potential to support the mission of burgeoning
health care delivery mechanisms (e.g. accountable care
organizations) that call for increased quality and effi-
ciency and reduced healthcare costs [41]. To ensure de-
cision aids’ maximal impact, however, the success of
various implementation strategies must be studied. At
present, there are multiple approaches to decision aid
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nity settings, in the office prior to the clinical visit, and
integrated into the clinical visit in full or abbreviated
form), but evidence is lacking to determine which ap-
proach results in the best outcomes [42,43]. Further, very
little work has been done to explore how integrating
decision aids into patient portals with prompts from the
electronic health records would impact clinical out-
comes. Investigating these topics could yield significant
insights and benefits for care delivery.
In considering our findings, readers should consider
the following limitations. First, our sample size was de-
termined by our ability to detect differences in our main
study outcome (CHD risk reduction), not the secondary
outcomes reported in this paper [32]. Future studies
should be powered specifically to look at decision mak-
ing outcomes. Second, baseline differences in education
among intervention and control patients raise the possi-
bility of unmeasured confounding. Third, appropriate
measures of coaching success are unknown. We chose
to measure coaching success using the presence of CHD
discussions and a validated scale of patients’ perceptions
of their interaction with their provider. Other measures
of coaching may yield additional or different insights.
Fourth, our examination of the impact of various com-
ponents of the decision aid should be viewed as prelim-
inary only. Subgroups were small and our study design
did not allow assessment of the independent effects of
decision aid components. Fifth, the patient sample was
mostly white, highly educated, and had high self-efficacy.
Results, therefore, may not generalize to more diverse
patient populations.
Conclusions
Limitations aside, this study shows that decision aids
can play an important role in improving decisions about
CHD prevention and increasing CHD discussions and
intent to reduce CHD risk. Additional insights might be
gained by studying the effects of decision aids on more
diverse populations, with additional measures of coach-
ing success, and more diverse strategies for decision aid
implementation.
Additional file
Additional file 1: Messages for Individuals Choosing No Options for
CHD prevention.
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